Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in Seronegative Generalized Myasthenia Gravis
NCT06587867Phase 3Recruiting
- Sponsor
- University Health Network
- Start
- Jun 2023
- Primary completion
- May 2025
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by University Health Network. Primary endpoint: Total Myasthenia Gravis Impairment Index at 42 weeks. Started Jun 2023; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06587867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06587867.